Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

Cancer Treatment Reviews

Volumn 30, Issue 7, 2004, Pages 609-641

  Graaf, Matthijs R ^a   Richel, Dick J ^a   van Noorden, Cornelis J F ^a   Guchelaar, Henk Jan ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Farnesyltransferase inhibitors; HMG CoA reductase inhibitors; Mevalonate pathway; Statins

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ANTINEOPLASTIC AGENT; ATORVASTATIN; BIM 46228; BISPHOSPHONIC ACID DERIVATIVE; BMS 186511; CELL CYCLE PROTEIN; CERIVASTATIN; CISPLATIN; CLOFIBRATE; CYTARABINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONAFARNIB; MANUMYCIN; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RPR 115135; SCH 56582; SIMVASTATIN; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISEASE; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLIOMA CELL; HEADACHE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKEMIA CELL LINE; LUNG NON SMALL CELL CANCER; LYMPHOMA CELL LINE; MELANOMA CELL; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PANCREAS CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYDIPSIA; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL TRACT; UREMIA; VISUAL IMPAIRMENT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; NEOPLASTIC PROCESSES; SIGNAL TRANSDUCTION;

EID: 7544219925     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.06.010     Document Type: Review

References (318)

1. M. Simons P. Keller J. Dichgans J.B. Schulz Cholesterol and Alzheimer's disease: Is there a link Neurology 57 2001 1089-1093
2. H. Jick G.L. Zornberg S.S. Jick S. Seshadri D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627-1631
3. B. Wolozin W. Kellman P. Ruosseau G.G. Celesia G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439-1443
4. J.C. Coons Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management Ann Pharmacother 36 2002 326-330
5. J.L. Goldstein M.S. Brown Regulation of the mevalonate pathway Nature (London) 343 1990 425-430
6. P.J. Casey Protein lipidation in cell signaling Science 268 1995 221-225
7. R.R. Rando Chemical biology of protein isoprenylation/methylation Biochim Biophys Acta 1300 1996 5-16
8. J.L. Bos Ras oncogenes in human cancer: A review Cancer Res 49 1989 4682-4689
9. D.C. Crick D.A. Andres R. Danesi M. Macchia C.J. Waechter Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells J Neurochem 70 1998 2397-2405
10. A. Vogt Y. Qian T.F. McGuire A.D. Hamilton S.M. Sebti Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts Oncogene 13 1996 1991-1999
11. P.M. Ghosh N. Ghosh-Choudhury M.L. Moyer et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line Oncogene 18 1999 4120-4130
12. M. Jakobisiak S. Bruno J.S. Skierski Z. Darzynkiewicz Cell cycle-specific effects of lovastatin Proc Natl Acad Sci USA 88 1991 3628-3632
13. K. Keyomarsi L. Sandoval V. Band A.B. Pardee Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin Cancer Res 51 1991 3602-3609
14. waf/cip1 in human prostate carcinoma cells J Biol Chem 273 1998 10618-10623
15. R.J. Macaulay W. Wang J. Dimitroulakos L.E. Becker H. Yeger Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro J Neurooncol 42 1999 1-11
16. S. Rao D.C. Porter X. Chen T. Herliczek M. Lowe K. Keyomarsi et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Proc Natl Acad Sci USA 96 1999 7797-7802
17. W. Wang R. Macauley Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines Can J Neurol Sci 26 1999 305-310
18. C. Park I. Lee W.K. Kang Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death Carcinogenesis 22 2001 1727-1731
19. N.W. van de Donk M.M. Kamphuis H.M. Lokhorst A.C. Bloem The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells Leukaemia (Baltimore) 16 2002 1362-1371
20. R.H. Weiss A. Ramirez A. Joo Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase J Am Soc Nephrol 10 1999 1880-1890
21. F. Schmidt P. Groscurth M. Kermer J. Dichgans M. Weller Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells Acta Neuropathol 101 2001 217-224
22. J.B. Rubins T. Greatens R.A. Kratzke A.T. Tan V.A. Polunovsky P. Bitterman Lovastatin induces apoptosis in malignant mesothelioma cells Am J Respir Crit Care Med 157 1998 1616-1622
23. D. Perez-Sala F. Mollinedo Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells Biochem Biophys Res Commun 199 1994 1209-1215
24. M. Marcelli G.R. Cunningham S.J. Haidacher et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP Cancer Res 58 1998 76-83
25. L. Maksumova K. Ohnishi F. Muratkhodjaev et al. Increased sensitivity of multidrug-resistant myeloid leukaemia cell lines to lovastatin Leukaemia (Baltimore) 14 2000 1444-1450
26. J.S. Kim F. Pirnia Y.H. Choi et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint Oncogene 19 2000 6082-6090
27. K.D. Jones W.T. Couldwell D.R. Hinton et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells Biochem Biophys Res Commun 205 1994 1681-1687
28. J. Dimitroulakos D. Nohynek K.L. Backway et al. Increased sensitivity of acute myeloid leukaemias to lovastatin-induced apoptosis: A potential therapeutic approach Blood 93 1999 1308-1318
29. J. Dimitroulakos L.Y. Ye M. Benzaquen et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications Clin Cancer Res 7 2001 158-167
30. M. Buemi A. Allegra M. Senatore et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells Eur J Pharmacol 370 1999 201-203
31. J.W. Choi S.E. Jung Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells J Pharmacol Exp Ther 289 1999 572-579
32. Z. Xia M.M. Tan W.W.L. Wong J. Dimitroulakos M.D. Minden L.Z. Penn Blocking protein geranygeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukaemia cells Leukaemia (Baltimore) 15 2001 1398-1407
33. S. Sumi R.D. Beauchamp C.M. Townsend Jr. et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin Gastroenterology 103 1992 982-989
34. C. DeNoyelle M. Vasse M. Korner et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study Carcinogenesis 22 2001 1139-1148
35. A. Thibault D. Samid A.C. Tompkins et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 1996 483-491
36. W.W. Wong M.M. Tan Z. Xia J. Dimitroulakos M.D. Minden L.Z. Penn Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin Clin Cancer Res 7 2001 2067-2075
37. P. Negre-Aminou A.K. van Vliet M. van Erck G.C. van Thiel R.E. van Leeuwen L.H. Cohen Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types Biochim Biophys Acta 1345 1997 259-268
38. W.A. Maltese R. Defendini R.A. Green K.M. Sheridan D.K. Donley Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase J Clin Invest 76 1985 1748-1754
39. S.M. Sebti G.T. Tkalcevic J.P. Jani Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice Cancer Commun 3 1991 141-147
40. H. Iishi M. Tatsuta M. Baba rasp21 isoprenylation inhibition induces flat colon tumors in wistar rats Dis Colon Rectum 43 2000 70-75
41. T. Narisawa M. Morotomi Y. Fukaura M. Hasebe M. Ito R. Aizawa Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats Jpn J Cancer Res 87 1996 798-804
42. T. Narisawa Y. Fukaura N. Tanida M. Hasebe M. Ito R. Aizawa Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice Tohoku J Exp Med 180 1996 131-138
43. M. Murakami T. Goto Y. Saito S. Goto M. Kochi Y. Ushio The inhibitory effect of simvastatin on growth in malignant gliomas - with special reference to its local application with fibrin glue spray in vivo Int J Oncol 19 2001 525-531
44. C.J.F. Van Noorden L.C. Meade-Tollin F.T. Bosman Metastasis: The spread of cancer cells to distant sites implies a complex series of cellular abnormalities caused, in part, by genetic aberrations Am Sci 86 1998 130-141
45. I.K. Wang S.Y. Lin-Shiau J.K. Lin Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology (Basel) 59 2000 245-254
46. F. Ganne M. Vasse J.L. Beaudeux et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis Thromb Haemost 84 2000 680-688
47. B. Wong W.C. Lumma A.M. Smith J.T. Sisko S.D. Wright T.Q. Cai Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation J Leukoc Biol 69 2001 959-962
48. D.F. Alonso H.G. Farina G. Skilton M.R. Gabri M.S. De Lorenzo D.E. Gomez Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis Breast Cancer Res Treat 50 1998 83-93
49. P. Matar V.R. Rozados M.M. Binda E.A. Roggero R.D. Bonfil O.G. Scharovsky Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma Clin Exp Metastasis 17 1999 19-25
50. P. Prasanna A. Thibault L. Liu D. Samid Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells J Neurochem 66 1996 710-716
51. J.P. Jani S. Specht N. Stemmler et al. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis Invasion Metastasis 13 1993 314-324
52. T. Kusama M. Mukai T. Iwasaki et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Cancer Res 61 2001 4885-4891
53. L. Vincent W. Chen L. Hong et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect FEBS Lett 495 2001 159-166
54. W.J. Kort W.C. Hulsmann T.E. Stehman Modulation of metastatic ability by inhibition of cholesterol synthesis Clin Exp Metastasis 7 1989 517-523
55. T. Kusama M. Mukai T. Iwasaki et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis Gastroenterology 122 2002 308-317
56. A.C. Knapp J. Huang G. Starling P.A. Kiener Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death Atherosclerosis 152 2000 217-227
57. G. Rogler K.J. Lackner G. Schmitz Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro Am J Cardiol 76 1995 114A-116A
58. Y. Hidaka T. Eda M. Yonemoto T. Kamei Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733) Atherosclerosis 95 1992 87-94
59. S. Unlu G. Clunn M. Schachter C. Demoliou-Mason A.D. Hughes Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein J Cardiovasc Pharmacol 38 2001 161-173
60. A. Corsini F. Pazzucconi L. Arnaboldi et al. Direct effects of statins on the vascular wall J Cardiovasc Pharmacol 31 1998 773-778
61. D.I. Axel R. Riessen H. Runge R. Viebahn K.R. Karsch Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures J Cardiovasc Pharmacol 35 2000 619-629
62. C. Guijarro L.M. Blanco-Colio M. Ortego et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 83 1998 490-500
63. H.J. Park D. Kong L. Iruela-Arispe U. Begley D. Tang J.B. Galper 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA Circ Res 91 2002 143-150
64. L. Vincent C. Soria F. Mirshahi Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models Arterioscler Thromb Vasc Biol 22 2002 623-629
65. W. Feleszko E.Z. Balkowiec E. Sieberth et al. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis Int J Cancer 81 1999 560-567
66. M. Weis C. Heeschen A.J. Glassford J.P. Cooke Statins have biphasic effects on angiogenesis Circulation 105 2002 739-745
67. Y. Kureishi Z. Luo I. Shiojima et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004-1010
68. C. Urbich E. Dernbach A.M. Zeiher S. Dimmeler Double-edged role of statins in angiogenesis signaling Circ Res 90 2002 737-744
69. Z. Ungvari P. Pacher A. Csiszar Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF Med Hypotheses 58 2002 85-86
70. M. Simons Molecular multitasking: Statins lead to more arteries, less plaque Nat Med 6 2000 965-966
71. U. Laufs V.L. Fata J.K. Liao Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase J Biol Chem 272 1997 31725-31729
72. A. Brouet P. Sonveaux C. Dessy S. Moniotte J.L. Balligand O. Feron Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins Circ Res 89 2001 866-873
73. M.D. Siperstein V.M. Fagan Studies on the feed-back regulation of cholesterol synthesis Adv Enzyme Regul 2 1964 249-264
74. M.D. Siperstein V.M. Fagan Deletion of the cholesterol-negative feedback system in liver tumors Cancer Res 24 1964 1108-1115
75. M.D. Siperstein Cholesterol, cholesterogenesis and cancer Adv Exp Med Biol 369 1995 155-166
76. H. Buchwald Cholesterol inhibition, cancer, and chemotherapy Lancet 339 1992 1154-1156
77. M.L. Littman T. Taguchi E.H. Mosbach Effect of cholesterol-free, fat-free diet and hypocholesteremic agents on growth of transplantable animal tumors Cancer Chemother Rep 50 1966 25-45
78. P.D. Schneider E.K. Chan I.J. Guzman R.D. Rucker R.L. Varco H. Buchwald Retarding Novikoff tumor growth by altering host rat cholesterol metabolism Surgery 87 1980 409-416
79. M. Michikawa K. Yanagisawa Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death J Neurochem 72 1999 2278-2285
80. M.R. Soma A. Corsini R. Paoletti Cholesterol and mevalonic acid modulation in cell metabolism and multiplication Toxicol Lett (Shannon) 64-65 1992 1-15
81. M.F. McCarty Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation Med Hypotheses 56 2001 12-16
82. O. Larsson Cell cycle-specific growth inhibition of human breast cancer cells induced by metabolic inhibitors Glycobiology 3 1993 475-479
83. L. Girnita M. Wang Y. Xie et al. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: Therapeutic implications Anticancer Drug Des 15 2000 67-72
84. M. Carlberg A. Dricu H. Blegen et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth J Biol Chem 271 1996 17453-17462
85. A. Dricu M. Wang M. Hjertman et al. Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc Glycobiology 7 1997 625-633
86. R. Girgert Y. Vogt D. Becke G. Bruchelt P. Schweizer Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms Cancer Lett 137 1999 167-172
87. S.A. Holstein R.J. Hohl Interaction of cytosine arabinoside and lovastatin in human leukaemia cells Leuk Res 25 2001 651-660
88. T. Kikuchi Y. Nagata T. Abe In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells J Neurooncol 34 1997 233-239
89. B. Agarwal S. Bhendwal B. Halmos S.F. Moss W.G. Ramey P.R. Holt Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells Clin Cancer Res 5 1999 2223-2229
90. B. Agarwal C.V. Rao S. Bhendwal et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac Gastroenterology 117 1999 838-847
91. T. Tanaka I. Tatsuno D. Uchida et al. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition J Neurosci 20 2000 2852-2859
92. T. Terano T. Shiina Y. Noguchi et al. Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells J Atheroscler Thromb 5 1998 1-6
93. A. Hirai S. Nakamura Y. Noguchi et al. Geranylgeranylated rho small GTPase (s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells J Biol Chem 272 1997 13-16
94. C. Guijarro L.M. Blanco-Colio Z.A. Massy et al. Lipophilic statins induce apoptosis of human vascular smooth muscle cells Kidney Int Suppl 71 1999 88-91
95. G.J. Pronk J.L. Bos The role of p21ras in receptor tyrosine kinase signalling Biochim Biophys Acta 1198 1994 131-147
96. A. Hall Rho GTPases and the actin cytoskeleton Science (Washington, DC) 279 1998 509-514
97. S. Aznar J.C. Lacal Rho signals to cell growth and apoptosis Cancer Lett 165 2001 1-10
98. P. Adamson C.J. Marshall A. Hall P.A. Tilbrook Post-translational modifications of p21rho proteins J Biol Chem 267 1992 20033-20038
99. S.A. Armstrong V.C. Hannah J.L. Goldstein M.S. Brown CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB J Biol Chem 270 1995 7864-7868
100. M.Y. Chang M.S. Jan S.J. Won H.S. Liu Ha-rasVal12 oncogene increases susceptibility of NIH/3T3 cells to lovastatin Biochem Biophys Res Commun 248 1998 62-68
101. J.E. DeClue W.C. Vass A.G. Papageorge D.R. Lowy B.M. Willumsen Inhibition of cell growth by lovastatin is independent of ras function Cancer Res 51 1991 712-717
102. P.M. Ghosh M.L. Moyer G.E. Mott J.I. Kreisberg Effect of cyclin E overexpression on lovastatin-induced G1 arrest and RhoA inactivation in NIH3T3 cells J Cell Biochem 74 1999 532-543
103. G. Koch C. Benz G. Schmidt C. Olenik K. Aktories Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton J Pharmacol Exp Ther 283 1997 901-909
104. B. Agarwal B. Halmos A.S. Feoktistov et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells Carcinogenesis 23 2002 521-528
105. J. Adnane Z. Chen J. Ohkanda M. Kothare A. Hamilton S.M. Sebti Upregulation of RhoB transcription, not inhibition of RhoB prenylation, as a potential mechanism by which farnesyltransferase and geranylgeranyltransferase I inhibitors suppress human tumor growth Proc Am Assoc Cancer Res 42 2001 1406
106. A. Skaletz-Rorowski J.G. Muller A. Kroke et al. Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition Eur J Cell Biol 80 2001 207-212
107. H.L. Bouterfa V. Sattelmeyer S. Czub D. Vordermark K. Roosen J.C. Tonn Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells Anticancer Res 20 2000 2761-2771
108. M. Takata M. Urakaze R. Temaru et al. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase Br J Pharmacol 134 2001 753-762
109. X.Q. Xu T.F. McGuire M.A. Blaskovich S.M. Sebti G. Romero Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts Arch Biochem Biophys 326 1996 233-237
110. D.T. Dudley L. Pang S.J. Decker A.J. Bridges A.R. Saltiel A synthetic inhibitor of the mitogen-activated protein kinase cascade Proc Natl Acad Sci USA 92 1995 7686-7689
111. S.R. Datta H. Dudek X. Tao et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231-241
112. L. del Peso M. Gonzalez-Garcia C. Page R. Herrera G. Nunez Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 278 1997 687-689
113. A. Iwama M. Sawamura Y. Nara Y. Yamori Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF Clin Exp Pharmacol Physiol 22 Suppl 1 1995 318-320
114. H. Nakagawa T. Mutoh T. Kumano M. Kuriyama Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts FEBS Lett 508 2001 53-56
115. T.F. McGuire S.J. Corey S.M. Sebti Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor J Biol Chem 268 1993 22227-22230
116. T.F. McGuire X.Q. Xu S.J. Corey G.G. Romero S.M. Sebti Lovastatin disrupts early events in insulin signaling: A potential mechanism of lovastatin's anti-mitogenic activity Biochem Biophys Res Commun 204 1994 399-406
117. H. Nakagawa T. Mutoh T. Kumano M. Kuriyama HMG-CoA reductase inhibitor-induced L6 myoblast cell death: Involvement of the phosphatidylinositol 3-kinase pathway FEBS Lett 438 1998 289-292
118. P. Rodriguez-Viciana P.H. Warne R. Dhand et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature (London) 370 1994 527-532
119. J. Dimitroulakos S. Thai G.H. Wasfy D.W. Hedley M.D. Minden L.Z. Penn Lovastatin induces a pronounced differentiation response in acute meyloid leukaemias Leuk Lymphoma 40 2000 167-178
120. L.M. Blanco-Colio A. Villa M. et al. Ortego 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation Atherosclerosis 161 2002 17-26
121. W.H. Park Y.Y. Lee E.S. Kim et al. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis Anticancer Res 19 1999 3133-3140
122. N. Garcia-Roman A.M. Alvarez M.J. Toro A. Montes M.J. Lorenzo Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition Mol Cell Neurosci 17 2001 329-341
123. K.T. Nguyen W.J. Wang J.L. Chan L.H. Wang Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells Oncogene 19 2000 5385-5397
124. C. Rommel B.A. Clarke S. Zimmermann et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt Science (Washington, DC) 286 1999 1738-1741
125. S. Zimmermann K. Moelling Phosphorylation and regulation of Raf by Akt (protein kinase B) Science (Washington, DC) 286 1999 1741-1744
126. H.P. Reusch S. Zimmermann M. Schaefer M. Paul K. Moelling Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells J Biol Chem 276 2001 33630-33637
127. K. Moelling K. Schad M. Bosse S. Zimmermann M. Schweneker Regulation of Raf-Akt Cross-talk J Biol Chem 277 2002 31099-31106
128. R.A. Weinberg The retinoblastoma protein and cell cycle control Cell 81 1995 323-330
129. K. Pruitt C.J. Der Ras and Rho regulation of the cell cycle and oncogenesis Cancer Lett 171 2001 1-10
130. L. Hengst V. Dulic J.M. Slingerland E. Lees S.I. Reed A cell cycle-regulated inhibitor of cyclin-dependent kinases Proc Natl Acad Sci USA 91 1994 5291-5295
131. L. Hengst S.I. Reed Translational control of p27Kip1 accumulation during the cell cycle Science (Washington, DC) 271 1996 1861-1864
132. A. Wachtershauser J. Stein Butyrate-induced differentiation of Caco-2 cells occurs independently from p27 Biochem Biophys Res Commun 281 2001 295-299
133. A. Vogt J. Sun Y. Qian A.D. Hamilton S.M. Sebti The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 (WAF1/CIP1/SDI1) in a p53-independent manner J Biol Chem 272 1997 27224-27229
134. A. Giermasz M. Makowski E. Kozlowska et al. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice Int J Cancer 97 2002 746-750
135. J. Gray-Bablin S. Rao K. Keyomarsi Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion Cancer Res 57 1997 604-609
136. U. Laufs D. Marra K. Node J.K. Liao 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1) J Biol Chem 274 1999 21926-21931
137. Y. Katayose M. Kim A.N. Rakkar Z. Li K.H. Cowan P. Seth Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27 Cancer Res 57 1997 5441-5445
138. K. Polyak T. Waldman T.C. He K.W. Kinzler B. Vogelstein Genetic determinants of p53-induced apoptosis and growth arrest Genes Dev 10 1996 1945-1952
139. S. Rao J. Gray-Bablin T.W. Herliczek K. Keyomarsi The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway Exp Cell Res 252 1999 211-223
140. A. Vidal S.S. Millard J.P. Miller A. Koff Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status J Biol Chem 277 2002 16433-16440
141. J.D. Weber W. Hu S.C. Jefcoat Jr. D.M. Raben J.J. Baldassare Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27 J Biol Chem 272 1997 32966-32971
142. W. Hu C.J. Bellone J.J. Baldassare RhoA stimulates p27 (Kip) degradation through its regulation of cyclin E/CDK2 activity J Biol Chem 274 1999 3396-3401
143. R.J. Sheaff M. Groudine M. Gordon J.M. Roberts B.E. Clurman Cyclin E-CDK2 is a regulator of p27Kip1 Genes Dev 11 1997 1464-1478
144. A. Montagnoli F. Fiore E. Eytan et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation Genes Dev 13 1999 1181-1189
145. M.F. Olson H.F. Paterson C.J. Marshall Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 Nature (London) 394 1998 295-299
146. E.H. Danen P. Sonneveld A. Sonnenberg K.M. Yamada Dual stimulation of Ras/mitogen-activated protein kinase and RhoA by cell adhesion to fibronectin supports growth factor-stimulated cell cycle progression J Cell Biol 151 2000 1413-1422
147. Z. Yang T. Kozai B. van der Loo et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins J Am Coll Cardiol 36 2000 1691-1697
148. S. Rao M. Lowe T.W. Herliczek K. Keyomarsi Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53 Oncogene 17 1998 2393-2402
149. T.B. Newman S.B. Hulley Carcinogenicity of lipid-lowering drugs JAMA 275 1996 55-60
150. J.E. Dalen W.S. Dalton Does lowering cholesterol cause cancer JAMA 275 1996 67-69
151. P.B. Fowler WHO clofibrate/cholesterol trial: Clarifications Lancet 341 1993 314-315
152. J.A. Heady J.N. Morris M.F. Oliver WHO clofibrate/cholesterol trial: clarifications Lancet 340 1992 1405-1406
153. M.R. Law S.G. Thompson N.J. Wald Assessing possible hazards of reducing serum cholesterol Br Med J 308 1994 373-379
154. M.L. Pearce S. Dayton Incidence of cancer in men on a diet high in polyunsaturated fat Lancet 1 1971 464-467
155. J.R. Downs M. Clearfield S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA 279 1998 1615-1622
156. T.R. Pedersen L. Wilhelmsen O. Faergeman et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering Am J Cardiol 86 2000 257-262
157. F.M. Sacks M.A. Pfeffer L.A. Moye et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001-1009
158. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 1349-1357
159. The LIPID Study Group Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up Lancet 2002 359 1379-1387
160. L. Bjerre J. Lelorier Do statins cause cancer? A meta-analysis of large randomized clinical trials Am J Med 110 2001 716-723
161. P.R. Hebert J.M. Gaziano K.S. Chan C.H. Hennekens Cholesterol lowering with statin drugs, risk of stroke, and total mortality JAMA 278 1997 313-321
162. M.A. Pfeffer A. Keech F.M. Sacks et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project Circulation 105 2002 2341-2346
163. J. Shepherd G.J. Blauw M.B. Murphy et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet 360 2002 1623-1630
164. J.A. Kaye C.R. Meier A.M. Walker H. Jick Statin use, hyperlipidaemia, and the risk of breast cancer Br J Cancer 86 2002 1436-1439
165. Lovastatin Study Groups I, through IV, Lovastatin 5-year safety and efficacy study Arch Intern Med 153 1993 1079-1087
166. L. Blais A. Desgagné J. Lelorier 3-Hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors and the risk of cancer Arch Intern Med 160 2000 2363-2368
167. M.R. Graaf A.B. Beiderbeck A.C. Egberts D.Y. Richel H.Y. Guchelaar The risk of cancer in users of statins J Clin Oncol 22 2004 2388-2392
168. M. Takemoto K. Node H. Nakagami et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 108 2001 1429-1437
169. S. Wassmann U. Laufs A.T. Baumer et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase Mol Pharmacol 59 2001 646-654
170. Y. Rikitake S. Kawashima S. Takeshita et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits Atherosclerosis 154 2001 87-96
171. W.S. Kim M.M. Kim H.J. Choi et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma Invest New Drugs 19 2001 81-83
172. J. Larner J. Jane E. Laws R. Packer C. Myers M. Shaffrey A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am J Clin Oncol 21 1998 579-583
173. S. Kawata E. Yamasaki T. Nagase et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Br J Cancer 84 2001 886-891
174. S.R. Johnston Farnesyl transferase inhibitors: A novel targeted therapy for cancer Lancet Oncol 2 2001 18-26
175. F.G. Njoroge B. Vibulbhan D.F. Rane et al. Structure-activity relationship of 3-substituted
176. G.P. Prevost A. Pradines M.C. Brezak et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228 Int J Cancer 91 2001 718-722
177. P. Russo D. Malacarne C. Falugi S. Trombino P.M. O'Connor RPR-115135, a farnesyltransferase inhibitor, increases 5-FU-cytotoxicity in ten human colon cancer cell lines: Role of p53 Int J Cancer 100 2002 266-275
178. F. Tamanoi C.L. Gau C. Jiang H. Edamatsu J. Kato-Stankiewicz Protein farnesylation in mammalian cells: Effects of farnesyltransferase inhibitors on cancer cells Cell Mol Life Sci 58 2001 1636-1649
179. W.R. Bishop R. Bond J. Petrin et al. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells J Biol Chem 270 1995 30611-30618
180. M.M. Feldkamp N. Lau A. Guha Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects Oncogene 18 1999 7514-7526
181. A.D. Cox A.M. Garcia J.K. Westwick et al. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation J Biol Chem 269 1994 19203-19206
182. G.L. James J.L. Goldstein M.S. Brown et al. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells Science (Washington, DC) 260 1993 1937-1942
183. N.E. Kohl S.D. Mosser S.J. deSolms et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor Science (Washington, DC) 260 1993 1934-1937
184. V. Manne N. Yan J.M. Carboni et al. Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells Oncogene 10 1995 1763-1779
185. T. Nagasu K. Yoshimatsu C. Rowell M.D. Lewis A.M. Garcia Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956 Cancer Res 55 1995 5310-5314
186. W.C. Rose F.Y. Lee C.R. Fairchild et al. Preclinical antitumor activity of bms-214662, a highly apoptotic and novel farnesyltransferase inhibitor Cancer Res 61 2001 7507-7517
187. N. Suzuki K. Del Villar F. Tamanoi Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents Proc Natl Acad Sci USA 95 1998 10499-10504
188. P.F. Lebowitz D. Sakamuro G.C. Prendergast Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment Cancer Res 57 1997 708-713
189. N. Suzuki J. Urano F. Tamanoi Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells Proc Natl Acad Sci USA 95 1998 15356-15361
190. W. Wang R.J. Macaulay Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A Int. J. Cancer 82 1999 430-434
191. W.Z. Gu S.K. Tahir Y.C. Wang et al. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo Eur J Cancer 35 1999 1394-1401
192. J. Rak Y. Mitsuhashi L. Bayko et al. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis Cancer Res 55 1995 4575-4580
193. S. Charvat M. Duchesne P. Parvaz M.C. Chignol D. Schmitt M. Serres The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor Anticancer Res 19 1999 557-561
194. L. Sepp-Lorenzino Z. Ma E. Rands et al. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res 55 1995 5302-5309
195. D.W. End G. Smets A.V. Todd et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 61 2001 131-137
196. R.E. Barrington M.A. Subler E. Rands et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis Mol Cell Biol 18 1998 85-92
197. L.R. Kelland V. Smith M. Valenti et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer Clin Cancer Res 7 2001 3544-3550
198. N.E. Kohl C.A. Omer M.W. Conner et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat Med 1 1995 792-797
199. N.E. Kohl F.R. Wilson S.D. Mosser et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice Proc Natl Acad Sci USA 91 1994 9141-9145
200. R. Mangues T. Corral N.E. Kohl et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice Cancer Res 58 1998 1253-1259
201. P. Norgaard B.K. Law H.S. Plovisson H.L. Moses Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation Ann N Y Acad Sci 886 1999 265-268
202. P. Norgaard B. Law H. Joseph et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis Clin Cancer Res 5 1999 35-42
203. J. Sun Y. Qian A.D. Hamilton S.M. Sebti Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion Cancer Res 55 1995 4243-4247
204. C.A. Omer Z. Chen R.E. Diehl et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:pRotein transferase inhibitor Cancer Res 60 2000 2680-2688
205. D.G. Peters R.R. Hoover M.J. Gerlach et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukaemia and primary cells from patients with chronic myeloid leukaemia Blood 97 2001 1404-1412
206. A. Reichert N. Heisterkamp G.Q. Daley J. Groffen Treatment of Bcr/Abl-positive acute lymphoblastic leukaemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336 Blood 97 2001 1399-1403
207. Z. Zhang Y. Wang L.E. Lantry et al. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf Oncogene 22 2003 6257-6265
208. S. Mishra B. Zhang J. Groffen N. Heisterkamp A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukaemia/lymphoma caused by P190 Bcr/Abl Leukaemia 18 2004 23-28
209. M. Kurimoto Y. Hirashima H. Hamada et al. In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620 J Neurooncol 61 2003 103-112
210. J.B. Gibbs A. Oliff The potential of farnesyltransferase inhibitors as cancer chemotherapeutics Annu Rev Pharmacol Toxicol 37 1997 143-166
211. J.E. Karp S.H. Kaufmann A.A. Adjei J.E. Lancet J.J. Wright D.W. End Current status of clinical trials of farnesyltransferase inhibitors Curr Opin Oncol 13 2001 470-476
212. F.A. Eskens A. Awada D.L. Cutler et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors J Clin Oncol 19 2001 1167-1175
213. J.E. Lancet J.D. Rosenblatt J.E. Karp Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukaemias Semin Hematol 39 2002 31-35
214. A.A. Adjei C. Erlichman J.N. Davis et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity Cancer Res 60 2000 1871-1877
215. J.E. Karp J.E. Lancet S.H. Kaufmann et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukaemias: A phase 1 clinical-laboratory correlative trial Blood 97 2001 3361-3369
216. A.A. Adjei A. Mauer L. Bruzek et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 1760-1766
217. S.J. Cohen L. Ho S. Ranganathan et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma J Clin Oncol 21 2003 1301-1306
218. H. Reuveni T. Geiger B. Geiger A. Levitzki Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway J Cell Biol 151 2000 1179-1192
219. D. Park S.K. Pandey E. Maksimova S. Kole M. Bernier Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor Biochemistry 39 2000 12513-12521
220. D.B. Whyte P. Kirschmeier T.N. Hockenberry et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 1997 14459-14464
221. M.M. Feldkamp N. Lau L. Roncari A. Guha Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status Cancer Res 61 2001 4425-4431
222. P.F. Lebowitz G.C. Prendergast Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho Oncogene 17 1998 1439-1445
223. S.M. Sebti A.D. Hamilton Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies Oncogene 19 2000 6584-6593
224. P.F. Lebowitz J.P. Davide G.C. Prendergast Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity Mol Cell Biol 15 1995 6613-6622
225. E.C. Lerner T.T. Zhang D.B. Knowles Y. Qian A.D. Hamilton S.M. Sebti Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene 15 1997 1283-1288
226. P. Servais B. Gulbis D. Fokan P. Galand Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells Int J Cancer 76 1998 601-608
227. G.C. Prendergast J.P. Davide S.J. deSolms et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton Mol Cell Biol 14 1994 4193-4202
228. S.M. Sebti A.D. Hamilton Inhibition of Ras prenylation: A novel approach to cancer chemotherapy Pharmacol Ther 74 1997 103-114
229. T. Andreu T. Beckers E. Thoenes P. Hilgard H. von Melchner Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors J Biol Chem 273 1998 13848-13854
230. H. Travers N.S. French J.D. Norton Suppression of tumorigenicity in Ras-transformed fibroblasts by alpha 2 (I) collagen Cell Growth Differ 7 1996 1353-1360
231. W. Du P.F. Lebowitz G.C. Prendergast Elevation of alpha2 (I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors Cancer Res 59 1999 2059-2063
232. P.F. Lebowitz P.J. Casey G.C. Prendergast J.A. Thissen Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB J Biol Chem 272 1997 15591-15594
233. G. Zalcman V. Closson G. Linares-Cruz et al. Regulation of Ras-related RhoB protein expression during the cell cycle Oncogene 10 1995 1935-1945
234. W. Du P.F. Lebowitz G.C. Prendergast Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB Mol Cell Biol 19 1999 1831-1840
235. W. Du G.C. Prendergast Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors Cancer Res 59 1999 5492-5496
236. G.C. Prendergast R. Khosravi-Far P.A. Solski H. Kurzawa P.F. Lebowitz C.J. Der Critical role of Rho in cell transformation by oncogenic Ras Oncogene 10 1995 2289-2296
237. A. Liu W. Du J.P. Liu T.M. Jessell G.C. Prendergast RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors Mol Cell Biol 20 2000 6105-6113
238. Z. Chen J. Sun A. Pradines G. Favre J. Adnane S.M. Sebti Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice J Biol Chem 275 2000 17974-17978
239. H.R. Ashar L. James K. Gray et al. The farnesyl transferase inhibitor SCH 66336 induces a G (2)→M or G(1) pause in sensitive human tumor cell lines Exp Cell Res 262 2001 17-27
240. H.R. Ashar L. James K. Gray et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules J Biol Chem 275 2000 30451-30457
241. N. Crespo J. Ohkanda T. Yen A. Hamilton S. Sebti The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells J Biol Chem 276 2001 16161-16167
242. A. Abrieu J.A. Kahana K.W. Wood D.W. Cleveland CENP-E as an essential component of the mitotic checkpoint in vitro Cell 102 2000 817-826
243. T.L. Glass T.J. Liu W.K. Yung Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336 Neuro-Oncology 2 2000 151-158
244. E.C. Lerner Y. Qian M.A. Blaskovich et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes J Biol Chem 270 1995 26802-26806
245. G.L. James M.S. Brown M.H. Cobb J.L. Goldstein Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells J Biol Chem 269 1994 27705-27714
246. B.K. Law P. Norgaard L. Gnudi B.B. Kahn H.S. Poulson H.L. Moses Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway J Biol Chem 274 1999 4743-4748
247. K. Jiang D. Coppola N.C. Crespo et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis Mol Cell Biol 20 2000 139-148
248. A. Liu G.C. Prendergast Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors FEBS Lett 481 2000 205-208
249. H.A. Lane A. Fernandez N.J. Lamb G. Thomas p70s6k function is essential for G1 progression Nature (London) 363 1993 170-172
250. B.K. Law P. Norgaard H.L. Moses Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli J Biol Chem 275 2000 10796-10801
251. W. Du A. Liu G.C. Prendergast Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors Cancer Res 59 1999 4208-4212
252. W.C. Hung L.Y. Chaung The farnesyltransferase inhibitor, FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells Int J Oncol 12 1998 137-140
253. H. Edamatsu C.L. Gau T. Nemoto L. Guo F. Tamanoi Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines Oncogene 19 2000 3059-3068
254. M.M. Moasser N. Rosen The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer Breast Cancer Res Treat 73 2002 135-144
255. L. Sepp-Lorenzino N. Rosen A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells J Biol Chem 273 1998 20243-20251
256. N.M. Hamad J.H. Elconin A.E. Karnoub et al. Distinct requirements for Ras oncogenesis in human versus mouse cells Genes Dev 16 2002 2045-2057
257. D.L. Brassard J.M. English M. Malkowski P. Kirschmeier T.L. Nagabhushan W.R. Bishop Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras Exp Cell Res 273 2002 138-146
258. E. Cohen-Jonathan R.J. Muschel W. Gillies McKenna et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS Radiat Res 154 2000 125-132
259. W. Feleszko R. Zagozdzon J. Golab M. Jakobisiak Potentiated antitumour effects of ciplatin and lovastatin against MmB16 melanoma in mice Eur J Cancer 34 1998 406-411
260. W. Feleszko I. Mlynarczuk E.Z. Balkowiec-Iskra et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice Clin Cancer Res 6 2000 2044-2052
261. M. Liu M.S. Bryant J. Chen et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice Cancer Res 58 1998 4947-4956
262. L.L. Nielsen B. Shi G. Hajian et al. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models Cancer Res 59 1999 5896-5901
263. B. Shi B. Yaremko G. Hajian et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo Cancer Chemother Pharmacol 46 2000 387-393
264. J. Sun M.A. Blaskovich D. Knowles et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine Cancer Res 59 1999 4919-4926
265. G. Xu J. Pan C. Martin S.C. Yeung Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma J Clin Endocrinol Metab 86 2001 1769-1777
266. A.A. Adjei J.N. Davis L.M. Bruzek C. Erlichman S.H. Kaufmann Synergy of the protein farnesyltransferase inhibitor SCH663366 and cisplatin in human cancer cell lines Clin Cancer Res 7 2001 1438-1445
267. S.C. Yeung G. Xu J. Pan M. Christgen A. Bamiagis Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells Cancer Res 60 2000 650-656
268. P. Russo C. Ottoboni D. Malacarne A. Crippa J.F. Riou P.M. O'Connor Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: Role of p53 J Pharmacol Exp Ther 300 2002 220-226
269. M.M. Moasser L. Sepp-Lorenzino N.E. Kohl et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones Proc Natl Acad Sci USA 95 1998 1369-1374
270. R. Danesi W.D. Figg E. Reed C.E. Myers Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells Mol Pharmacol 47 1995 1106-1111
271. E. Wang C.N. Casciano R.P. Clement W.W. Johnson The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein Cancer Res 61 2001 7525-7529
272. E. Wang C.N. Casciano R.P. Clement W.W. Johnson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm Res (New York) 18 2001 800-806
273. J. Braess W. Hiddeman The widening role of statines: RAS signal transduction and drug-induced cytotoxicity in human leukaemia: A commentary to 'interaction of cytosine arabinoside and lovastatin in human leukaemia cells' Leuk Res 25 2001 661-663
274. A.C. Miller D. Samid Tumor resistance to oxidative stress: Association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation Int J Cancer 60 1995 249-254
275. A.C. Miller K. Kariko C.E. Myers E.P. Clark D. Samid Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation Int J Cancer 53 1993 302-307
276. E.J. Bernhard W.G. McKenna A.D. Hamilton et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes Cancer Res 58 1998 1754-1761
277. E.J. Bernhard G. Kao A.D. Cox et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Res 56 1996 1727-1730
278. S.M. Hahn E.J. Bernhard W. Regine et al. A phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer Clin Cancer Res 8 2002 1065-1072
279. E. Cohen-Jonathan S. Evans C. Koch et al. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras Cancer Res 61 2001 2289-2293
280. D. Amin S.A. Cornell S.K. Gustafson et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis J Lipid Res 33 1992 1657-1663
281. E. van Beek E. Pieterman L. Cohen C. Lowik S. Papapoulos Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo Biochem Biophys Res Commun 255 1999 491-494
282. J.D. Bergstrom R.G. Bostedor P.J. Masarachia A.A. Reszka G. Rodan Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch Biochem Biophys 373 2000 231-241
283. S.P. Luckman D.E. Hughes F.P. Coxon R. Graham G. Russell M.J. Rogers Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 1998 581-589
284. K. Thompson J.E. Dunford F.H. Ebetino M.J. Rogers Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase Biochem Biophys Res Commun 290 2002 869-873
285. F.P. Coxon H.L. Benford R.G. Russell M.J. Rogers Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs Mol Pharmacol 54 1998 631-638
286. C.M. Shipman P.I. Croucher R.G. Russell M.H. Helfrich M.J. Rogers The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 58 1998 5294-5297
287. S.S. Virtanen H.K. Vaananen P.L. Harkonen P.T. Lakkakorpi Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2002 2708-2714
288. V.B. Andela M. Pirri E.M. Schwarz et al. The mevalonate synthesis pathway as a therapeutic target in cancer Clin Orthop 415 2003 S59-S66
289. V.B. Andela J.D. Rosenblatt E.M. Schwarz E.J. Puzas R.J. O'Keefe R.N. Rosier Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis Clin Orthop Relat Res 397 2002 228-239
290. B. Vincenzi D. Santini G. Avvisati A. Baldi A.L. Cesa G. Tonini Statins may potentiate bisphosphonates anticancer properties: A new pharmacological approach Med Hypotheses 61 2003 98-101
291. K. Gwyn F.A. Sinicrope Chemoprevention of colorectal cancer Am J Gastroenterol 97 2002 13-21
292. S.S. Husain I.L. Szabo A.S. Tamawski NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action Am J Gastroenterol 97 2002 542-553
293. E.M. Moran Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks J Environ Pathol Toxicol Oncol 21 2002 193-201
294. B.K. Law M.E. Waltner-Law A.J. Entingh et al. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen J Biol Chem 275 2000 38261-38267
295. W. Feleszko A. Jalili D. Olszewska et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines Oncol Rep 9 2002 879-885
296. M.V. Swamy I. Cooma B.S. Reddy C.V. Rao Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens Int J Oncol 20 2002 753-759
297. F. Degraeve M. Bolla S. Blaie et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins J Biol Chem 276 2001 46849-46855
298. I. Inoue S. Goto K. Mizotani et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells Life Sci 67 2000 863-876
299. J. Sun Y. Qian A.D. Hamilton S.M. Sebti Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts Oncogene 16 1998 1467-1473
300. R.B. Lobell C.A. Omer M.T. Abrams et al. Evaluation of farnesyl:pRotein transferase and geranylgeranyl:pRotein transferase inhibitor combinations in preclinical models Cancer Res 61 2001 8758-8768
301. N. Sizemore A.D. Cox J.A. Barnard et al. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides Gastroenterology 117 1999 567-576
302. A.J. Mantha K.E. McFee N. Niknejad G. Goss I.A. Lorimer J. Dimitroulakos Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells J Cancer Res Clin Oncol 129 2003 631-641
303. G. Sauer H. Deissler C. Kurzeder R. Kreienberg New molecular targets of breast cancer therapy Strahlenther Onkol 178 2002 123-133
304. R. Asslan A. Pradines G. Favre F. Le Gaillard Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells Biochem J 330 Pt 1 1998 241-246
305. R. Asslan A. Pradines C. Pratx C. Allal G. Favre F. Le Gaillard Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells Biochem Biophys Res Commun 260 1999 699-706
306. M. O'Dwyer Multifaceted approach to the treatment of bcr-abl-positive leukaemias Oncologist 7 Suppl. 1 2002 30-38
307. P. le Coutre E. Tassi M. Varella-Garcia et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758-1766
308. S.B. Marley R.J. Davidson J.M. Goldman M.Y. Gordon Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia Br J Haematol 116 2002 162-165
309. R.R. Hoover F.X. Mahon J.V. Melo G.Q. Daley Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336 Blood 100 2002 1068-1071
310. A. Awada F.A. Eskens M. Piccart et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours Eur J Cancer 38 2002 2272-2278
311. J. Zujewski I.D. Horak C.J. Bol et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer J Clin Oncol 18 2000 927-941
312. M. Crul G.J. de Klerk M. Swart et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer J Clin Oncol 20 2002 2726-2735
313. J. Cortes M. Albitar D. Thomas et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukaemia and other hematologic malignancies Blood 101 2003 1692-1697
314. R. Kurzrock H.M. Kantarjian J.E. Cortes et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: Clinical and biologic activities in the phase 1 setting Blood 102 2003 4527-4534
315. M. Lishner A. Bar-Sef A. Elis I. Fabian Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukaemia cell lines J Invest Med 49 2001 319-324
316. M.R. Soma P. Pagliarini G. Butti R. Paoletti P. Paoletti R. Fumagalli Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells Cancer Res 52 1992 4348-4355
317. K. Kozar R. Kaminski M. Legat et al. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin Int J Oncol 24 2004 1149-1157
318. W. Wang E. Collie-Duguid J. Cassidy Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines FEBS Lett 531 2002 415-420